Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms

Ferrero, Simone; Drandi, Daniela; Mantoan, Barbara; Ghione, Paola; Omedè, Paola; Ladetto, Marco

doi:10.1002/hon.989

Cited by 36 publications

(28 citation statements)

References 93 publications

(132 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, the crucial thing is that designed ASO primers are not able to amplify healthy DNA; primers have to be specific for MM (ref. 31 ). The method used for MRD quantification is RQ-PCR with ASO primers and probes.…”

Section: Discussionmentioning

confidence: 99%

Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients

Sedlaříková¹,

Kubiczkova²,

Kryukov³

et al. 2015

BIOMED PAP

View full text Add to dashboard Cite

Aims. Multiple myeloma (MM), the second most common hematological cancer, is a lymphoproliferative disease of terminally differentiated B lymphocytes characterized by expansion of monoclonal plasma cells. With the introduction of new drugs, MM has become a hard-to-treat disease. The aim of treatment is clinical remission and eradication of clinical manifestations but most MM patients eventually relapse. For this reason, more accurate monitoring of remission and relapse using molecular biology techniques is at the center of attention. Methods. For monitoring, we used allele-specific PCR and quantitative real-time PCR based on specific detection of VDJ immunoglobulin heavy chain gene rearrangement of clonal cells for monitoring. The hypervariable region of IgH rearrangement is used for detection of minimal residual disease (MRD) in MM as this sequence is used for allele-specific primers and probe design. This technique is a complementary tool for flow cytometry in MRD detection; however, it has not been established in the Czech Republic so far.Results. Qualitative and quantitative MRD detection was performed in 50% (5/10) patients and qualitative MRD detection in another 3 oligoclonal patients. Conclusions. Next to flow cytometry, detection of MRD by qPCR is a viable option and has been introduced in the Czech Republic.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients

Sedlaříková¹,

Kubiczkova²,

Kryukov³

et al. 2015

BIOMED PAP

View full text Add to dashboard Cite

show abstract

“…PCR approaches for MRD detection do not require an immediate sample processing because they are unaffected by preanalytical biases such as loss of viable cells over time (38,39). Furthermore, the MRD target used is based on the uniqueness of clonal IGHV rearrangements which leads to a high sensitivity, adequate for MRD detection (10 À5 -10 À6 ; refs.…”

Section: Allele-specific Oligonucleotide Pcrmentioning

confidence: 99%

Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?

Paiva

Puig

García‐Sanz

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Increasing therapeutic options and prolonged survival in multiple myeloma have raised interest in the concept of depth of response and its importance to predict patients' outcomes. Although the efficacy of current treatment approaches has greatly improved in the past decade, the definition of complete response (CR) remains unaltered and continues to use conventional serological and morphologic techniques. That notwithstanding, there is growing interest in minimal residual disease (MRD) monitoring, which has emerged in recent years as one of the most relevant prognostic factors in multiple myeloma. MRD can be assessed both inside (e.g., immunophenotypic and molecular techniques) and outside the bone marrow (e.g., PET/CT). Here, we focus on flow- and molecular-based assays by which different cooperative groups have demonstrated the efficacy of MRD assessment to predict outcomes even among patients in CR, and irrespectively of disease risk. Although further standardization is still required, the time has come to implement MRD monitoring in prospective clinical trials as a sensitive tool to evaluate treatment efficacy and for risk-adapted treatment, particularly in the consolidation and maintenance settings. Here, we present a comprehensive and critical review on the methodologic aspects, specific characteristics, and clinical significance of MRD monitoring by flow cytometry, PCR, and next-generation sequencing. Clin Cancer Res; 21(9); 2001–8. ©2015 AACR.

show abstract

“…Moreover, the reappearance of MRD-positivity after a period of MR was associated with an increased risk of relapse with a median time between molecular and clinical relapse of 11 months. [54] Finally, the same group reported more recent results on the impact of non-myeloablative allo-SCT on MRD. The tandem approach auto-SCT followed by a non-myeloablative allo-SCT in newly diagnosed MM-induced MR (nested-PCR) in approximately 50% of patients at 12 months from SCT.…”

Section: Autologous Stem Cell Transplantation In Elderly Patientsmentioning

confidence: 93%

“…Three approaches are currently available and include allele-specific oligonucleotide PCR (ASO-PCR) and its most recent derivatives digital droplet PCR, MFC, and next-generation sequencing (NGS). [54][55][56][57][58][59] Characteristics of the three methods are compared in Table 2. Potential advantages of the recent introduction of NGS include a higher rate of target identification, non-reliance on patient-specific primers, possibility of performing sub-clone analyses, and possibly improved sensitivity.…”

Section: Autologous Stem Cell Transplantation In Elderly Patientsmentioning

confidence: 99%

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)

Bruno

Auner

Gahrton

et al. 2016

Leukemia & Lymphoma

Self Cite

View full text Add to dashboard Cite

The definitive version is available at: La versione definitiva è disponibile alla URL: [http://www.tandfonline.com.offcampus.dam.unito.it/doi/full/10.3109/10428194.2015.1131278] Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) AbstractThe European Society for Blood and Marrow Transplantation Chronic Malignancies Working Party held a preceptorship meeting in Turin, Italy on 25-26 September 2014, to discuss the role of stem cell transplantation (SCT) in the treatment of multiple myeloma and other plasma cell disorders. Scientists and clinicians working in the field gathered to discuss a variety of topics including the results of recent clinical trials, basic research, the concept of minimal residual disease, and immune modulation. As individual presentations revealed, important advances have occurred in our understanding of the pathophysiology of myeloma and the role that SCT, along with other forms of immunotherapy, plays in treating it. Each presentation stimulated discussion and exchange of ideas among the attendants. We decided to summarize and, importantly, to update the meeting proceedings in this review to share stimulating discussions and ideas on potentially novel treatment strategies among clinicians.

show abstract

Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms

Cited by 36 publications

References 93 publications

Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients

Detection of tumor-specific marker for minimal residual disease in multiple myeloma patients

Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)

Contact Info

Product

Resources

About